Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089–100.

Article  PubMed  Google Scholar 

GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396:1223–49.

Article  Google Scholar 

Centers for Disease Control and Prevention. Chronic kidney disease in the united States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prvention; 2023.

Google Scholar 

Feng X, Hou N, Chen Z, Liu J, Li X, Sun X, et al. Secular trends of epidemiologic patterns of chronic kidney disease over three decades: an updated analysis of the global burden of disease study 2019. BMJ Open. 2023;13:e064540.

Article  PubMed  PubMed Central  Google Scholar 

Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ. Reduction in cardiovascular death after kidney transplantation. Transplantation. 2010;89:851.

Article  PubMed  Google Scholar 

Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic health: A presidential advisory from the American heart association. Circulation. 2023;148:1606–35.

Article  PubMed  Google Scholar 

Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392:2052–90.

Article  PubMed  PubMed Central  Google Scholar 

Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108:2154–69.

Article  PubMed  Google Scholar 

Matsushita K, Ballew SH, Wang AY-M, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18:696–707.

Article  PubMed  Google Scholar 

Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Ren Physiol. 2006;290:F262–272.

Article  CAS  Google Scholar 

Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

Article  CAS  PubMed  Google Scholar 

United States Renal Data System. 2024 USRDS Annual Data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2024.

Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.

Article  Google Scholar 

Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lamprea-Montealegre JA, McClelland RL, Astor BC, Matsushita K, Shlipak M, de Boer IH, et al. Chronic kidney disease, plasma lipoproteins, and coronary artery calcium incidence: the Multi-Ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:652–8.

Article  CAS  PubMed  Google Scholar 

Katzmann JL, Werner CM, Stojakovic T, März W, Scharnagl H, Laufs U. Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study. Lipids Health Dis. 2020;19:116.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14:727–49.

Article  CAS  PubMed  Google Scholar 

Reiss AB, Voloshyna I, De Leon J, Miyawaki N, Mattana J. Cholesterol metabolism in CKD. Am J Kidney Dis. 2015;66:1071–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shroff R, Speer T, Colin S, Charakida M, Zewinger S, Staels B, et al. HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol. 2014;25:2658–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol. 2014;18:234–7.

Article  CAS  PubMed  Google Scholar 

Shaik A, Kosiborod M, de Lemos JA, Gao Q, Mues KE, Alam S, et al. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from getting to an improved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD). Clin Cardiol. 2022;45:1303–10.

Article  PubMed  PubMed Central  Google Scholar 

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: A report of the American college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140:e563–95.

PubMed  PubMed Central  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: A report of the American college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:3168–209.

Article  PubMed  Google Scholar 

Zac-Varghese S, Mark P, Bain S, Banerjee D, Chowdhury TA, Dasgupta I, et al. Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the joint association of British clinical diabetologists and UK kidney association (ABCD-UKKA) guideline 2024. BMC Nephrol. 2024;25:216.

Article  PubMed  PubMed Central  Google Scholar 

Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol Lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2022;80:1366–418.

Article  PubMed  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.

Article  PubMed  Google Scholar 

Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9:129–69.

Article  PubMed  Google Scholar 

Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303–9.

Article  CAS  PubMed  Google Scholar 

Kidney Disease. Improving global outcomes (KDIGO) CKD work group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117–314.

Article  Google Scholar 

Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of Statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013;20:641–57.

Article  PubMed  Google Scholar 

Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of Pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–63.

Article  CAS  PubMed  Google Scholar 

Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid Lowering with Atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to new Targets) study. J Am Coll Cardiol. 2008;51:1448–54.

Article  CAS  PubMed  Google Scholar 

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, To